Research graph
References from Engineering phage therapeutics with intrinsic biocontainment. Local targets link to admitted publications; unresolved targets remain external evidence.
Bacteriophages presence in nature and their role in the natural selection of bacterial populations
2020 · External reference
Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures
10.1057/s41599-020-0478-4 · 2020 · External reference
Regulations of phage therapy across the world
10.3389/fmicb.2023.1250848 · 2023 · External reference
Current clinical landscape and global potential of bacteriophage therapy
10.3390/v15041020 · 2023 · External reference
Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study
10.1038/s41564-024-01705-x · 2024 · External reference
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review
10.1016/s1473-3099(21)00612-5 · 2022 · External reference
The safety and efficacy of phage therapy: a systematic review of clinical and safety trials
10.3390/antibiotics11101340 · 2022 · External reference
Antibiotic resistance: a current epilogue
10.1016/j.bcp.2016.12.005 · 2017 · External reference
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
10.1016/s0140-6736(21)02724-0 · 2022 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2019 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2022 · External reference
Regulation of phage therapy medicinal products: developments, challenges, and opportunities
10.3389/fcimb.2025.1631359 · 2025 · External reference
Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections
10.1128/cmr.00044-24 · 2024 · External reference
The future of clinical phage therapy in the United Kingdom
10.3390/v15030721 · 2023 · External reference
Bacteria–phage infection network structure and genomic defence system content predict efficacy of a phage therapy cocktail against Pseudomonas aeruginosa from chronic lung infections
10.1098/rstb.2024.0080 · 2025 · External reference
Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance
10.1038/s41467-025-64608-3 · 2025 · External reference
Bridging the gap: phage manufacturing processes from laboratory to agri-food industry
10.1016/j.virusres.2025.199537 · 2025 · External reference
Systematic and scalable genome-wide essentiality mapping to identify nonessential genes in phages
10.1371/journal.pbio.3002416 · 2023 · External reference
Current challenges and future opportunities of phage therapy
10.1093/femsre/fuaa017 · 2020 · External reference
A phylogenetic host-range index reveals ecological constraints in phage specialisation and virulence
10.1111/mec.70052 · 2025 · External reference
The unregulated potential of phages
10.1016/s2666-5247(23)00043-5 · 2023 · External reference
Phage therapy in Europe: regulatory and intellectual property protection issues
2019 · External reference
The patentability of natural phages as therapeutics in the United States
10.36922/mi.4758 · 2024 · External reference
Engineering modular viral scaffolds for targeted bacterial population editing
10.1016/j.cels.2015.08.013 · 2015 · External reference
Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus
10.1038/s41591-019-0437-z · 2019 · External reference
Synthetic engineering and biological containment of bacteriophages
10.1073/pnas.2206739119 · 2022 · External reference
Designing P. aeruginosa synthetic phages with reduced genomes
10.1038/s41598-021-81580-2 · 2021 · External reference
Engineering bacteriophages as versatile biologics
10.1016/j.tim.2018.09.006 · 2019 · External reference
Leveraging machine learning and big data techniques to map the global patent landscape of phage therapy
10.1038/s41587-024-02493-9 · 2024 · External reference
Engineered bacteriophages containing anti-CRISPR suppress infection of antibiotic-resistant P. aeruginosa
10.1128/spectrum.01602-22 · 2022 · External reference
Interpretation guidance for MHRA regulatory considerations for phage therapeutic products
10.1099/mic.0.001613 · 2025 · External reference
Engineering stringent genetic biocontainment of yeast with a protein stability switch
10.1038/s41467-024-44988-8 · 2024 · External reference
Designing a simple and efficient phage biocontainment system using the amber suppressor initiator tRNA
10.1007/s00705-024-06170-9 · 2024 · External reference
Bacteriophages and their genomes
10.1016/j.coviro.2011.06.009 · 2011 · External reference
Bacteriophage recombineering in the lytic state using the lambda red recombinases
10.1111/j.1751-7915.2011.00292.x · 2012 · External reference
Site-specific recombination of T2 phage using IP008 long tail fiber genes provides a targeted method for expanding host range while retaining lytic activity
10.1111/j.1574-6968.2009.01588.x · 2009 · External reference
Generating a synthetic genome by whole genome assembly: φX174 bacteriophage from synthetic oligonucleotides
10.1073/pnas.2237126100 · 2003 · External reference
Recombineering
10.4161/bact.18778 · 2012 · External reference
BRED: a simple and powerful tool for constructing mutant and recombinant bacteriophage genomes
10.1371/journal.pone.0003957 · 2008 · External reference
Continuous multiplexed phage genome editing using recombitrons
10.1038/s41587-024-02370-5 · 2025 · External reference
Genome editing of phylogenetically distinct bacteria using cross-species retron-mediated recombineering
10.1038/s41587-026-03076-6 · 2026 · External reference
Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system
10.4161/rna.27766 · 2014 · External reference
Optimization of T4 phage engineering via CRISPR/Cas9
10.1038/s41598-020-75426-6 · 2020 · External reference
A fully decompressed synthetic bacteriophage øX174 genome assembled and archived in yeast
10.1016/j.virol.2012.09.020 · 2012 · External reference
A synthetic biology approach to assemble and reboot clinically relevant Pseudomonas aeruginosa tailed phages
10.1128/spectrum.02897-23 · 2024 · External reference
Cell-free synthesis of infective phages from in vitro assembled phage genomes for efficient phage engineering and production of large phage libraries
2024 · External reference
Good guide, bad guide: spacer sequence-dependent cleavage efficiency of Cas12a
10.1093/nar/gkz1240 · 2020 · External reference
Structure-guided discovery of anti-CRISPR and anti-phage defense proteins
10.1038/s41467-024-45068-7 · 2024 · External reference
Phage engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens
10.1002/btm2.10381 · 2023 · External reference
Generative design of novel bacteriophages with genome language models
2025 · External reference
Refactoring bacteriophage T7
10.1038/msb4100025 · 2005 · External reference
Cell-free production of personalized therapeutic phages targeting multidrug-resistant bacteria
10.1016/j.chembiol.2022.06.003 · 2022 · External reference
Dispersing biofilms with engineered enzymatic bacteriophage
10.1073/pnas.0704624104 · 2007 · External reference
Mastering complexity: towards bottom-up construction of multifunctional eukaryotic synthetic cells
10.1016/j.tibtech.2018.03.008 · 2018 · External reference
Phage-based applications in synthetic biology
10.1146/annurev-virology-092917-043544 · 2018 · External reference
Efficient assembly of DNA using yeast homologous recombination (YHR)
2017 · External reference
Saturation mutagenesis genome engineering of infective ΦX174 bacteriophage via unamplified oligo pools and Golden Gate assembly
10.1021/acssynbio.9b00411 · 2020 · External reference
Rational design of high-number dsDNA fragments based on thermodynamics for the construction of full-length genes in a single reaction
10.1371/journal.pone.0145682 · 2015 · External reference
Enhanced Golden Gate Assembly: evaluating overhang strength for improved ligation efficiency
10.1093/nar/gkae809 · 2024 · External reference
Cross-genus rebooting of custom-made, synthetic bacteriophage genomes in L-form bacteria
10.1073/pnas.1714658115 · 2018 · External reference
PHEIGES: all-cell-free phage synthesis and selection from engineered genomes
10.1038/s41467-024-46585-1 · 2024 · External reference
Methodologies to increase the transformation efficiencies and the range of bacteria that can be transformed
10.1007/s00253-009-2349-1 · 2010 · External reference
SpyPhage: a cell-free TXTL platform for rapid engineering of targeted phage therapies
10.1021/acssynbio.2c00244 · 2022 · External reference
Cell free bacteriophage synthesis from engineered strains improves yield
10.1021/acssynbio.3c00239 · 2023 · External reference
The all-E. coli TXTL toolbox 3.0: new capabilities of a cell-free synthetic biology platform
2021 · External reference
Cell-free expression system: a promising platform for bacteriophage production and engineering
10.1186/s12934-025-02661-9 · 2025 · External reference
Synthesis of headful packaging phages through yeast transformation-associated recombination
10.3390/v17010045 · 2025 · External reference
Protocol for end-design-free rebooting of terminally redundant Pseudomonas phages in clinical isolates of Pseudomonas aeruginosa
10.1016/j.xpro.2025.104012 · 2025 · External reference
Next-generation biocontainment systems for engineered organisms
10.1038/s41589-018-0056-x · 2018 · External reference
Safety by design: biosafety and biosecurity in the age of synthetic genomics
10.1016/j.isci.2023.106165 · 2023 · External reference
Biocontainment of genetically modified organisms by synthetic protein design
10.1038/nature14121 · 2015 · External reference
Recoded organisms engineered to depend on synthetic amino acids
10.1038/nature14095 · 2015 · External reference
Cas9-assisted biological containment of a genetically engineered human commensal bacterium and genetic elements
10.1038/s41467-024-45893-w · 2024 · External reference
Bacteria–phage coevolution as a driver of ecological and evolutionary processes in microbial communities
10.1111/1574-6976.12072 · 2014 · External reference
Cross-border dialogue: an international survey of regulators on phage therapy
10.1016/j.ijantimicag.2025.107614 · 2025 · External reference
Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trial
10.1136/bmjopen-2022-065401 · 2022 · External reference
Phage therapy: eco-physiological pharmacology
2014 · External reference
Phage therapy could be key to conquering persistent bacterial lung infections in children
10.1038/s44259-024-00045-4 · 2024 · External reference
Drivers and consequences of bacteriophage host range
10.1093/femsre/fuad038 · 2023 · External reference
Synthetic biology approaches to biological containment: pre-emptively tackling potential risks
10.1042/ebc20160013 · 2016 · External reference
Rates of mutation and recombination in Siphoviridae phage genome evolution over three decades
10.1093/molbev/msy027 · 2018 · External reference
Controlling recombination to evolve bacteriophages
10.3390/cells13070585 · 2024 · External reference
Phage therapy: combating evolution of bacterial resistance to phages
10.3390/v17081094 · 2025 · External reference
Phage therapy: a targeted approach to overcoming antibiotic resistance
10.1016/j.micpath.2024.107088 · 2024 · External reference
‘Deadman’ and ‘passcode’ microbial kill switches for bacterial containment
10.1038/nchembio.1979 · 2016 · External reference
The bacteriophage decides own tracks: when they are with or against the bacteria
2021 · External reference
Development of a replication-deficient bacteriophage reporter lacking an essential baseplate wedge subunit
10.3390/v16010008 · 2023 · External reference
Deletion of the essential gene 24 from the bacteriophage T4 genome
10.1016/0378-1119(93)90541-a · 1993 · External reference
Biocontainment of phages inhibits bacterial clearance in micro niches
2026 · External reference
Discovering riboswitches: the past and the future
10.1016/j.tibs.2022.08.009 · 2023 · External reference
Engineered riboswitches control gene expression by small molecules
10.1042/bst0330474 · 2005 · External reference
T7 phage-assisted evolution of riboswitches using error-prone replication and dual selection
10.1038/s41598-024-52049-9 · 2024 · External reference
Artificial riboswitches for gene expression and replication control of DNA and RNA viruses
10.1073/pnas.1318563111 · 2014 · External reference
Degron-controlled protein degradation in Escherichia coli: new approaches and parameters
10.1021/acssynbio.3c00768 · 2024 · External reference
Genetic circuits in synthetic biology: broadening the toolbox of regulatory devices
10.3389/fsybi.2025.1548572 · 2025 · External reference
Emerging applications of riboswitches – from antibacterial targets to molecular tools
10.1007/s13353-016-0341-x · 2016 · External reference
Exploring the modular nature of riboswitches and RNA thermometers
10.1093/nar/gkw232 · 2016 · External reference
Systematic evaluation of genetic and environmental factors affecting performance of translational riboswitches
10.1021/acssynbio.9b00017 · 2019 · External reference
Refactored genetic codes enable bidirectional genetic isolation
10.1126/science.add8943 · 2022 · External reference
Multilayered genetic safeguards limit growth of microorganisms to defined environments
10.1093/nar/gku1378 · 2015 · External reference
Genetically engineered phages: a review of advances over the last decade
10.1128/mmbr.00069-15 · 2016 · External reference
Exploring perceptions of bacteriophage use in the UK across the One Health spectrum: a roundtable discussion
10.1093/sumbio/qvae030 · 2024 · External reference
Phage therapy and the public: increasing awareness essential to widespread use
10.1371/journal.pone.0285824 · 2023 · External reference
Perception of phage therapy and research across selected professional and social groups in Poland
10.3389/fpubh.2025.1490737 · 2025 · External reference
Public awareness, acceptability and risk perception about infectious diseases dual-use research of concern: a cross-sectional survey
10.1136/bmjopen-2019-029134 · 2020 · External reference
